Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057760 | 0.88 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL22095642 | 0.87 | SIGMAR1 (0.83) | SIGMAR1TMEM97 | |
| SCHEMBL22095049 | 0.87 | SIGMAR1 (0.97) | SIGMAR1TMEM97 | |
| SCHEMBL22095287 | 0.85 | SIGMAR1 (0.79) | SIGMAR1TMEM97 | |
| SCHEMBL22095614 | 0.83 | SIGMAR1 (0.74) | SIGMAR1TMEM97 | |
| SCHEMBL22095072 | 0.83 | SIGMAR1 (0.85) | SIGMAR1TMEM97 | |
| SCHEMBL22095585 | 0.81 | SIGMAR1 (0.72) | SIGMAR1TMEM97 | |
| SCHEMBL22095185 | 0.80 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL22095080 | 0.80 | SIGMAR1 (0.71) | SIGMAR1TMEM97 | |
| SCHEMBL30058176 | 0.80 | SIGMAR1 (0.70) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363649-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-11-17 | — | — | US | claimed |
| EP-3893892-A1 | ORGANIC COMPOUNDS | Rutgers, the State University of New Jersey (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123847-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-18 | — | — | WO | claimed |
| US-20220363649-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-11-17 | — | — | US | disclosed |
| WO-2021252709-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING SIGMA RECEPTOR RELATED DISEASES AND/OR DISORDERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3893892-A1 | ORGANIC COMPOUNDS | Rutgers, the State University of New Jersey (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123847-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363649-A1 | ORGANIC COMPOUNDS | TRPA1, OPRL1, ALG3 | SIGMAR1 451/4885TMEM97 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.